TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has shared an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced a board meeting scheduled for August 26, 2025, to discuss and approve the interim results for the first half of 2025 and consider the recommendation of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and strategic direction, potentially impacting stakeholders’ perceptions and the company’s market positioning.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative cancer immunotherapies. The company is involved in creating treatments that harness the body’s immune system to combat cancer, positioning itself within the competitive biopharmaceutical industry.
Average Trading Volume: 4,785,213
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.88B
For an in-depth examination of 1541 stock, go to TipRanks’ Overview page.